ten23 health ® and Neumirna Therapeutics team up to develop RNA therapy for epilepsy and other neurological diseases

 

 

The partnership aims to accelerate clinical translation of NMT.001, a microRNA-targeting RNA therapy for drug-resistant epilepsy.

 

ten23 health, the human-centric and sustainable strategic CDMO partner of choice for the pharmaceutical industry and biotech start-ups, is excited to announce its collaboration with Neumirna Therapeutics (‘Neumirna’), a biotechnology company developing RNA-based therapies for neurological diseases.

The two companies will collaborate to advance NMT.001, a microRNA–targeting antisense oligonucleotide (ASO) designed to treat drug-resistant epilepsy, towards clinical development. The goal is to bring the therapy into clinical trials, combining ten23’s formulation and manufacturing expertise with Neumirna’s RNA innovation.

“We are honored to collaborate with Neumirna Therapeutics and support their mission to address critical medical needs through innovative healthcare solutions,” said Dr. Susanne Jörg, COO of ten23 health. “Our expertise and ongoing research in drug product development, manufacturing, and testing of oligonucleotide therapies, including RNA, align seamlessly with Neumirna's commitment to delivering life-changing therapies. We share a common goal of improving patient care, and look forward to advancing this program effectively and efficiently.” 

“Partnering with ten23 health strengthens our ability to accelerate the development of our pipeline while maintaining the highest standards of quality,” said Dr. Ellen Donnelly, CEO at Neumirna Therapeutics. “Their proven track record and expertise support our vision of bringing novel therapies to patients in need. Together, we are taking a decisive step forward in advancing healthcare innovation.” 

The partnership arrives at a time of growing momentum for RNA and oligonucleotide-based therapies, particularly in areas with limited treatment options, such as chronic neurological diseases. ten23’s integrated services - spanning development, manufacturing, and testing - will enable faster and more robust advancement of complex therapies, and support biotechs like Neumirna on their path to commercialization.

Travels: Hôtel & Ryads Barrière Le Naoura, a rare interlude where art de vivre meets sporting elegance

                           

 

Just steps away from the legendary Jemâa el-Fna Square, shielded from the bustle of the medina, Hôtel & Ryads Barrière Le Naoura reveals a luxurious haven in the heart of the Red City. Conceived as an oasis of serenity, the property seamlessly blends French art de vivre with the richness of Moroccan hospitality, offering a rare experience where intimacy, elegance, and a passion for sport converge. 

 Exceptional Ryads — a home in Marrakech Beyond its 78 rooms and 7 suites, Le Naoura features 26 spectacular ryads, true architectural jewels at the foot of the Atlas Mountains. Designed to offer complete freedom, these private residences ranging from 240 to 450 sqm include 3 to 6 bedrooms, spacious Moroccan and European lounges, a fully equipped kitchen, and a private pool to experience Marrakech at its finest. Each ryad comes with the attentive service of a dedicated butler, available 24/7, ensuring a tailor-made stay where every detail is meticulously curated. Whether for a family getaway, a stay with friends or an exclusive golf retreat, these ryads embody the promise of an authentic, intimate, and generous luxury. 

Marrakech, a world-class golf destination For several years, Marrakech has established itself as one of the world’s most remarkable golfing destinations. Ideally located, Le Naoura partners with ten prestigious courses, all just minutes away from the hotel. Palmeraies, desert landscapes, panoramic views of the Atlas Mountains, bougainvillea and hibiscus — each course offers breathtaking scenery and a unique playing experience for golfers of all levels. The hotel’s concierge team provides seamless, bespoke support: tee time reservations, private transfers, equipment care and storage, and tailored recommendations — allowing guests to indulge their passion for golf with effortless elegance.  

   

 The Barrière experience: a celebration of art de vivre and excellence Staying at Hôtel & Ryads Barrière Le Naoura means embracing a rare interlude where every moment embodies French art de vivre and Moroccan warmth. After a round on Marrakech’s most beautiful greens, guests return to an oasis of refinement: inventive, locavore cuisine signed by Hamza Afquir at Fouquet’s Marrakech, the Spa Diane Barrière, a true sanctuary of well-being inspired by ancestral Moroccan rituals, a heated outdoor pool nestled in lush gardens, and a sunlit fitness center. Every detail reflects the same promise — elegance, generosity, and the Barrière signature — for an unforgettable luxury experience. 

**About Hôtel & Ryads Barrière Le Naoura Marrakech Opened in 2009, Le Naoura is an emblematic Barrière address in Morocco. Nestled in a lush oasis just steps from the medina, the property combines discreet luxury, exceptional service, and French art de vivre. With 78 rooms, 7 suites, 26 private ryads, two restaurants, a spa, a heated outdoor pool and partnerships with 10 prestigious golf courses, Le Naoura offers an exclusive escape designed for discerning travelers seeking serenity and unforgettable moments.   

     

Study confirms that people with ADHD can be more creative. The reason may be that they let their mind wander

 

New research confirms that ADHD (Attention Deficit Hyperactivity Disorder) can be linked to increased creativity and suggests that this creativity is associated with a greater tendency to let your mind wander. This first study to explain the link between ADHD and creativity, is presented at the ECNP congress in Amsterdam.

Lead researcher Han Fang (from the Radboud University Medical Centre, the Netherlands) said:
“Previous research pointed to mind wandering as a possible factor linking ADHD and creativity, but until now no study has directly examined this connection. We conducted two studies, utilising 2 different groups of ADHD patients and healthy controls, one from a European group curated by the ECNP, and a second study from a UK group. In total there were 750 participants. Separately analysing results from 2 independent groups means that we can have greater confidence in the results”.
 
The researchers examined the correlations between ADHD characteristics,  creativity, and functional impairments and the role of mind wandering in those links. Both patient groups showed classic ADHD characteristics, such as lack of attention, impulsivity, and the tendency to let one’s mind wander away from the subject in hand. Both studies showed that more ADHD symptoms were correlated with more mind wandering.
 
Mind wandering is defined as shifting attention away from the task at hand toward internally generated thoughts. Everyone is subject to a certain amount of mind wandering, but this is seen more in people with ADHD.
 
Han Fang added:
 
“Previous researchers have been able to distinguish two different types of mind wandering. It can be a loss of concentration, where your mind may drift from subject to subject. This is ‘spontaneous mind-wandering’.  Another type is ‘deliberate mind wandering’, where people give themselves the freedom to drift off-subject, where they ‘allow their thoughts to take a different course’. Psychiatrists have developed ways of measuring how much people are subject to these different tendencies”.
 
The researchers also measured creativity in both groups (there are standards ways of measuring this, for example by asking people to find  a creative use for an everyday object). They then looked at how creativity was associated with the different types of mind wandering.  
 
Dr Han Fang said:
 
“We found that people with more ADHD traits such as lack of attention, hyperactivity, or impulsivity, score higher on creative achievements in both studies. This supports previous research. Additionally, we found that mind wandering, particularly deliberate mind wandering, where people allow their “thoughts to wander on purpose”, was associated with greater creativity in people with ADHD. This suggests that mind wandering may be an underlying factor connecting ADHD and creativity.
 
This may have practical implications, for both psychoeducation and treatment. For psychoeducation, specially designed programs or courses that teach individuals how to utilize their spontaneous ideas, for example turning them into creative outputs, could help individuals with ADHD traits harness the benefits of mind wandering. For treatment, ADHD-tailored mindfulness-based interventions that seek to decrease spontaneous mind wandering or transform it into more deliberate forms may reduce functional impairments and enhance treatment outcomes. This is the first time this link has been investigated, so we need to see more studies which confirm the findings”.
 
Commenting, K.P. Lesch (Professor of Molecular Psychiatry, University of Würzburg, Germany) said
"Mind wandering is one of the critical resources on which the remarkable creativity of high-functioning ADHD individuals is based. This makes them such an incredibly valuable asset for our society and the future of our planet”.

ADHD: women are diagnosed five years later than men, despite symptoms appearing at the same age

  

 
 
Scientists have found that ADHD (Attention-Deficit/Hyperactivity Disorder) in women is diagnosed approximately 5 years later than in men, despite symptoms appearing at the same age. Women with ADHD also suffer greater emotional and functional difficulties than men. This work will be presented at the ECNP Congress in Amsterdam, after recent publication.
 
Lead researcher Dr Silvia Amoretti (Barcelona) said:
 
“ADHD affects millions of people, but our understanding of how it presents and impacts males and females differently remains limited. We found that females are underdiagnosed, often receiving a diagnosis years later than males. This delay may lead to worse clinical outcomes, including depression, anxiety, and functional impairment. Males on the other hand showed a higher level of involvement in delinquent behaviours such as legal problems and driving-related difficulties. We believe that a better understanding these sex-based differences might improve diagnosis and treatment.”
 
The researchers analysed a large clinical sample of 900 adults (54.9% male, 45.1% female, average age 36.94) diagnosed with ADHD for the first time at a specialized outpatient program in Barcelona. They assessed differences between males and females in terms of age at diagnosis, ADHD symptom severity, psychiatric comorbidities, psychosocial functioning, and disability. Participants underwent a standardized battery of clinical interviews and validated rating scales. They found that females had been diagnosed with ADHD at an average age of 28.96 years, whereas males were diagnosed at age 24.13 on average. Symptoms appeared in both males and females at approximately the same age. Males were around 3 times more likely to have encountered legal problems (18.1%) than were females (6.6%).
 
Silvia Amoretti said:
 
“We found that although ADHD symptoms started at a similar age in males and females, women were diagnosed about five years later. By the time of diagnosis, they showed more severe symptoms, worse functioning in daily life, and higher rates of depression and anxiety.
 
This is important because it shows that ADHD often goes unnoticed in women until it becomes a serious problem. Our findings suggest that we may be missing the early signs in girls and women, especially when their symptoms are less disruptive but still impactful. This has clear implications for earlier screening and sex-sensitive diagnostic tools.
 
We didn’t set out to compare the age of diagnosis in males and females, we were aiming to understand the general age when symptoms appear, regardless of sex. This finding was not part of our initial hypotheses but became evident during the analysis but became evident during the analysis, and the scale of the difference in diagnosis between the sexes was a surprise.
 
It’s likely that women are diagnosed later because the symptoms of ADHD manifest themselves differently in men and women. Boys are more likely to be hyperactive or impulsive, and this behaviour is more visible to parents, teachers and clinicians. On the other hand, girls with ADHD are more likely to seem inattentive and generally less disruptive. This becomes clinically important, as it means that women are just not treated early enough, and often are just not diagnosed at all. We have seen similar tendencies internationally, so it is likely that this is a global problem. The nature of the condition leads to poorer diagnosis in women everywhere, meaning that women can lose on average five years of treatment, 5 years of a better life”.
 
Commenting, Professor Sandra Kooij (Amsterdam UMC/VUmc and PsyQ, the Hague, the Netherlands) said:
 
“This study by Sylvia Amoretti and colleagues shows the delay in diagnosis in girls and women with ADHD compared to boys and males. Different presentation of symptoms, lack of awareness among clinicians that women have ADHD too, and the hormonal changes leading to severe mood instability in the last week of the cycle are all responsible for the gender differences in time to diagnosis of ADHD. 
 
Increasing awareness in both society and medicine helps girls and women to get earlier help when they need it”.  
 

Psychiatry’s Biggest Antidepressant Trial Just Got Reanalyzed: “It May Have Misled Treatment for Decades”, Experts Claim

 Overmedication is one of fastest rising problems in psychiatry field worldwide

New findings challenge STAR*D, the 4,000-patient government study that shaped depression treatment guidelines for years. Reanalysis shows no clear benefit of follow-up antidepressants over placebo, and experts weigh in on the need for alternative treatment methods.

 A new analysis published in the Journal of Clinical Psychopharmacology casts doubt on one of the most influential studies in modern psychiatry. When re-evaluated against randomized, placebo-controlled trials, most of the medication strategies used in the STAR*D trial, long seen as the gold standard for stepwise antidepressant care, show no measurable benefit beyond placebo.

The review compared STAR*D’s major treatment steps to real-world randomized controlled trial outcomes. Raising the SSRI dose, switching to another antidepressant, and adding common medications like bupropion or buspirone all failed to outperform placebo in blinded trials. 

The only add-on with consistent clinical benefit was lithium – which is constantly prescribed less and is harder to access due to known toxic effects on, e.g., the thyroid gland and the kidneys.  

“This study is a wake-up call,” said Dr. Hannah Nearney, clinical psychiatrist and UK Medical Director at Flow Neuroscience, a company that develops neuromodulation therapies for depression treatment. “Patients who don’t respond to the first antidepressant are often placed on a carousel of tweaks – higher doses, add-on pills, lateral switches – that produce side effects without providing real relief.”

An estimated 70% of patients with depression do not achieve remission with their first medication. Yet existing guidelines, based heavily on the STAR*D trial, still recommend drug modifications that, as reanalysis revealed, appear scientifically weak.

The new findings suggest these treatment steps may be driven more by expectation and placebo effects than by pharmacological mechanisms.

“This mirrors what we see every day in practice,” added Dr. Kultar Singh Garcha, NHS GP and Flow’s Global Medical Director. “Patients are stuck in trial-and-error cycles, not because we lack alternatives – but because those alternatives haven’t been prioritized in funding or regulation.”

One of those alternatives is transcranial direct current stimulation (tDCS) – a wearable, non-invasive brain stimulation technology backed by clinical trials. Flow Neuroscience, whose CE-certified device is already used in the NHS, says the findings highlight an urgent need to expand access to safe, proven, non-drug interventions.

“While tens of millions continue to cycle through barely effective drug combinations, validated neuromodulation therapies are still being overlooked or overregulated,” added Dr. Nearney. “We must give patients options grounded in science, and it must stay up-to-date. We’re living in a time where depression is becoming the next epidemic.”

The study’s authors argue for a rethinking of depression treatment models. As it claims, not all medications are ineffective – but the common practice of escalating doses or stacking drugs without placebo-controlled evidence may be doing more harm than good.

“This doesn’t mean medication should be abandoned,” Dr. Garcha concluded. “But if we’re going to recommend a new drug step, it has to outperform staying the course – not just look promising in an unblinded study. Otherwise, we’re replacing one flawed approach with another.”

 

ten23 health® kickstarts new era with launch of industry-first robot-assisted pilot non-GMP sterile filling in its Basel facilities

  ten23 health®, the human-centric and sustainable contract development, testing and manufacturing organization (CDTMO), today announced the launch of its “Line 0” (non-GMP) pilot sterile fill & finish services from its Basel (BASE®) facilities. The first-of-its-kind, custom-designed and purpose-built pilot sterile filling line is a co-development with Optima. The robot-based, small-scale filling machine is suitable for ready-to-use (RTU) and bulk containers, including vials, syringes, and cartridges, in combination with a 1.1 m² sized freeze-dryer (lyophiliser).

With development and preclinical costs increasingly under pressure, Line 0 offers the pharmaceutical industry an exciting new option for a wide range of key tasks. Customers will be able to take advantage of perfectly scaled-down, time- and cost-efficient process development services, and access aseptically produced drug product batches that do not require GMP grade. The pilot line avoids the extra costs and constraints of performing such activities in GMP manufacturing facilities or using non-representative equipment in labs.

“We will add significant speed and value to our customers’ projects with this innovative technology and the additional services that seamlessly integrate with our sterile GMP manufacturing offerings. We can now provide complete solutions from the development and preclinical scale to clinical and commercial manufacturing scale, with purpose-built scaling and transfer in mind,” explains Prof. Dr. Hanns-Christian Mahler, Chief Enablement Officer (CEO) at ten23 health.

Operated under the ISO9001 quality management system, Line 0 is designed to provide aseptically filled batches which may be required for specific purposes such as the implementation of novel processes or primary packaging, stability testing, analytical reference materials, and preclinical study material.

The new offering is compatible with novel primary packaging as well as related process development and characterization assessments for filling, stopper setting and lyophilization processes. It seamlessly integrates different manufacturing scales at ten23, from the new Pilot “Line 0” (non-GMP) in BASE® (Basel) to the VIVA1® and VIVA2® GMP fill& finish lines (Visp), all of which Isolators in Class C environment in Annex 1 GMP compliance:  “Line 1” (for clinical and commercial use using ready-to-use (RTU)container) “Line 2” (for large-scale commercial and possibly clinical use using RTU container), to “Line 3” (for clinical and commercial bulk-vial liquid or lyophilizate manufacturing). All sterile manufacturing lines are based on Optima equipment platforms, enabling easy scale-up and ensuring they are fit-for-purpose for the specific needs of each customer.

“With the addition of the pilot line to our offering we can support our customers by supplying liquid and lyophilized batches early on in their development timeline, with a setup and process representative of later clinical or commercial GMP batches. Compatibility with our GMP filling lines allows seamless process scaleup and reliable supply throughout our customers’ molecules’ lifecycles,” adds Dr. Susanne Jörg, Chief Customer Delivery Officer (COO) at ten23 health.

HonorHealth Research Institute presents new findings in decades-long quest to conquer aggressive pancreatic cancer

 

Promising results of RMC-6236, in combination with other drug treatments, presented at annual meeting of AACR

 

HonorHealth Research Institute’s new downtown Phoenix laboratory has produced its first study, centered on a promising new treatment for pancreatic cancer, one of the most aggressive and difficult to treat of all malignancies. Study results were presented April 29 in Chicago at the annual meeting of the 58,000-member American Association for Cancer Research (AACR), the world’s largest professional organization of cancer investigators, caregivers and patient advocates. Study findings indicate that a newly discovered drug, RMC-6236, also known as Daraxonrasib, is a powerful inhibitor of RAS (including KRAS, NRAS and HRAS). These are commonly mutated cancer-causing genes that drive the formation of many types of tumors, including pancreatic cancer.  This study evaluated the effectiveness of RMC-6236 in patient-derived pancreatic tumors harboring KRAS mutations. New: Center for Translational Science According to this initial study to emerge from the Research Institute’s new Center for Translational Science laboratory, RMC-6236, when combined with other proven pancreatic cancer drugs, is a promising new agent against RAS, particularly KRASG12X. Existing KRASG12C inhibitors are unable to target other mutations and often have the unintended result of making patient tumors drug resistant. “The fibrotic tumor microenvironment in pancreatic cancer exacerbates therapy resistance, and combining RMC-6236 with other therapies could overcome both intrinsic and acquired resistances,” according to Taylor Bargenquast, a clinical research technician and lead author of the study abstract, which she presented at AACR. “These results demonstrate the efficacy of RMC-6236 when combined with other therapeutic agents in a pancreatic cancer model — a three-dimensional model of pancreatic cancer cells derived from patient biopsies,” said Sunil Sharma, M.D., director of the Center for Translational Science and the senior author of the study abstract. “The combination of RMC-6236 with standard chemotherapy and targeted therapies enhances its antitumor activity, suggesting a promising strategy for improving therapeutic outcomes in pancreatic cancer,” said Erkut Borazanci, M.D., another of the study’s authors, and medical director of the Institute’s Oncology Research Division. 52,000 Americans expected to die Pancreatic cancer is the third-leading cause of cancer-related death in the U.S., after lung and colorectal cancers, and is expected to contribute this year to the deaths of nearly 52,000 Americans. Contributing to this study — Evaluating the efficacy of RAS(ON) inhibitor RMC-6236 combined with chemotherapy and other targeted therapies in 3D models involving patients with KRAS-mutated pancreatic cancer — was the Phoenix-based Translational Genomics Research Institute (TGen), part of City of Hope. The study suggests that human clinical trials are warranted to further evaluate the safety and effectiveness of RMC-6236.

Researchers develop virtual reality-based system to improve psychiatric diagnosis

 

Researchers have developed a virtual reality-based system that shows promise in improving the differentiation between common mental health conditions, potentially paving the way for earlier and more personalised treatment. The work is published in the March edition of the peer-reviewed journal European Neuropsychopharmacology, with a subsequent (31 March) comment also being published in the same journal.

Accurate diagnosis remains one of the biggest challenges in psychiatry, with more than half of psychiatric patients changing their diagnosis within 10 years. Most psychiatric diagnoses rely on patients reporting their symptoms, but many mental health conditions share overlapping features. For example, apathy, hallucinations, and cognitive problems may be present in both schizophrenia and bipolar disorder, making it difficult to distinguish between the two. Misdiagnosis can lead to suboptimal treatment and poorer outcomes.

 Now, a group of Danish scientists have combined virtual reality with physiological measurements (such as skin conductivity) to explore a more objective method for identifying different mental health conditions.

 Lead researcher Professor Kamilla Miskowiak (University of Copenhagen) said, “This is an important step forward. Until now, diagnosis has largely depended on self-reporting of symptoms, but our findings suggest that virtual reality scenarios combined with physiological measures may help differentiate between similar conditions. This is an area where psychiatry has long faced difficulties.”

 The researchers recruited 100 participants, including individuals with bipolar disorder, borderline personality disorder, schizophrenia, and healthy controls. Participants were exposed to various immersive virtual reality scenarios designed to elicit emotional and physiological responses, such as a video of a crying baby, a discussion in a canteen, and a cramped elevator scenario. The researchers measured emotional responses and skin conductivity during these scenarios.

 Their results indicate that these responses differed systematically between diagnostic groups, suggesting that this approach has the potential to enhance diagnostic accuracy. However, larger studies are needed to confirm these findings and to explore how such methods might be used in clinical practice.

Professor Miskowiak said, “This study is part of the VIRDIS project, which aims to develop objective tools to support psychiatric diagnosis. Our initial findings are promising, but further large-scale research is needed to validate this approach and develop it into a practical clinical tool. We are now launching a follow-up study with 300 participants and implementing machine learning methods to improve individual-level diagnostic predictions. Our long-term goal is to improve early and personalised treatment for patients with mental health disorders.”

The European Neuropsychopharmacology paper has attracted attention since it was placed online, including a published commentary from Dr Sijia Liu at the Liaoning University of Traditional Chinese Medicine, Shenyang, China, stating:
 
“This study offers a groundbreaking approach to addressing the persistent challenges in psychiatric diagnosis and treatment by leveraging virtual reality (VR) technology. I suggest that future research should consider integrating artificial intelligence algorithms to analyse the extensive data generated from these VR scenarios. I believe this work holds significant promise for advancing our understanding and clinical practices in mental health care”.  
 
This project is a collaboration between the Copenhagen Mental Health Centre, Khora Virtual Reality and EXP360. This study was supported by the Ivan Nielsen Foundation. 

Travels: Domaine les Terres Bleues: a new luxury destination in the Hautes-Vosges (France)

                   

 

Adrien Feltz and his partner Alexia Courtois embark on a new hospitality adventure with the unveiling of Domaine les Terres Bleues, a preserved haven spanning 1 hectare in the heart of the Vallée des Lacs (Vosges), designed as an ode to contemplation and relaxation.

"We wanted to create a place that brings together everything we dream of finding during our own getaways as a couple — a space where every detail invites relaxation and intimacy" the couple shares.

Designed by architect Gérald Klauss and brought to life by the Decobois company, the property consists of two prestigious chalets, each accommodating two guests. Fully oriented outward to provide a constant connection with the surrounding nature, they combine noble materials, clean lines, and large bay windows, creating perfect harmony between the indoors and outdoors. Each chalet features a private 50m2 south-facing terrace with a jacuzzi, a cozy living area with a wood-burning fireplace, a freestanding bathtub, a sensory shower, and a king-size bed.

An ideal getawat to recharge and reconnect

This is the promise of a unique experience where luxury meets simplicity and authenticity. Eacg stay becomes an invitation to slow down, refocus, and savor the present moment. The property features an outdoor pool (heated from May to October), a mirror sauna nestled in the forest, a natural spring water bath, personalized treatments and massages by experienced practitioners, wellness activities (yoga, meditation, and sophrology sessions), and outdoor adventures (guided hikes, mountain bike rides, countryside picnics, and wildlife observation).

A rich territory, alive through the seasons

Nestled in the heart of the Vosges, nature lovers will be enchanted by the diversity of the landscapes, where deer, hinds, and foxes often make appearances. Gérardmer, the jewel of the Vosges, is home to the region’s largest natural lake, of glacial origin and situated at an altitude of 660m. Nicknamed the “lake of a thousand reflections,” it’s just a few minutes from the estate, with a well-marked 6 km walking trail allowing visitors to take in its full beauty. The town is also renowned for its Fantastic Film Festival, the Daffodil Festival (a bi-annual spring event), and the richness of its natural spaces.

In winter, the ski resorts of Gérardmer and La Bresse (the largest in Eastern France) are just a 10-minute drive away. The scenic Route des Crêtes, accessible by car or bike, offers breathtaking panoramas of the Vosges mountains, valleys, and lakes.

Domaine les Terres Bleues is located just a short distance from Alsace, 45 minutes from Colmar — the perfect opportunity to explore charming Alsatian villages and wander the vineyard trails to taste local wines.

Practical Information

Opening: May 12 

Address: 560 Rte du Valtin, 88400 Xonrupt-Longemer - Vallée des Lacs, Hautes Vosges 

Website: www.domaine-lesterresbleues.com 

Instagram: www.instagram.com/domaine_les_terres_bleues/

Rates: from 450€/night